Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Yahoo Finance14d
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Recently, Absci entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. Needham analyst Gil Blum writes that Absci sets ...
Benzinga.com14d
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci’s partnerships with Merck, AstraZeneca, and Almirall provide milestone ...
Yahoo Finance28d
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...
Morningstar28d
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Morningstar brands and products Company Portfolio ...
Mena FN28d
Absci And AMD Announce Collaboration And Strategic Investment To Accelerate The Future Of AI Drug Discovery
(MENAFN- GlobeNewsWire - Nasdaq) $20 Million Equity investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ...
Nasdaq28d
Absci Corporation Announces Strategic Collaboration with AMD to Enhance AI Drug Discovery Capabilities
Absci Corporation has announced a strategic partnership with AMD to utilize AMD Instinct™ accelerators and ROCm™ software for advancing AI-driven drug discovery, specifically in de novo ...